Liquidia Technologies (LQDA) Cut to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Liquidia Technologies (NASDAQ:LQDA) from a hold rating to a sell rating in a report released on Wednesday.

According to Zacks, “Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company’s product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States. “

Several other equities research analysts have also commented on LQDA. Needham & Company LLC initiated coverage on shares of Liquidia Technologies in a research report on Monday, August 20th. They set a buy rating and a $30.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of Liquidia Technologies in a research report on Monday, August 20th. They set a buy rating and a $22.00 target price on the stock. Cowen initiated coverage on shares of Liquidia Technologies in a research report on Monday, August 20th. They set an outperform rating and a $40.00 target price on the stock. Finally, Wedbush initiated coverage on shares of Liquidia Technologies in a research report on Tuesday, September 4th. They set an outperform rating and a $26.00 target price on the stock. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $36.50.

Shares of LQDA opened at $20.96 on Wednesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.27 and a current ratio of 6.27. Liquidia Technologies has a 1 year low of $10.52 and a 1 year high of $38.46.

Liquidia Technologies (NASDAQ:LQDA) last issued its earnings results on Wednesday, October 31st. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.26). The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $1.03 million. Sell-side analysts anticipate that Liquidia Technologies will post -7.32 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the business. NEA Management Company LLC purchased a new stake in shares of Liquidia Technologies during the 3rd quarter worth $68,193,000. Dean Capital Investments Management LLC purchased a new stake in shares of Liquidia Technologies during the 3rd quarter worth $1,483,000. Vanguard Group Inc. purchased a new stake in shares of Liquidia Technologies during the 3rd quarter worth $4,263,000. FMR LLC purchased a new stake in shares of Liquidia Technologies in the 3rd quarter worth about $6,729,000. Finally, BlackRock Inc. purchased a new stake in shares of Liquidia Technologies in the 3rd quarter worth about $5,924,000. Institutional investors own 27.07% of the company’s stock.

About Liquidia Technologies

Liquidia Technologies, Inc, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension.

Featured Article: Book Value Per Share in Stock Trading

Get a free copy of the Zacks research report on Liquidia Technologies (LQDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply